These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20829518)

  • 1. Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit.
    Saver JL; Gornbein J; Starkman S
    Stroke; 2010 Oct; 41(10):2381-90. PubMed ID: 20829518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.
    ; Levine SR; Khatri P; Broderick JP; Grotta JC; Kasner SE; Kim D; Meyer BC; Panagos P; Romano J; Scott P;
    Stroke; 2013 Sep; 44(9):2500-5. PubMed ID: 23847249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
    Rao NM; Levine SR; Gornbein JA; Saver JL
    Stroke; 2014 Sep; 45(9):2728-33. PubMed ID: 25096731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.
    Saver JL; Yafeh B
    Stroke; 2007 Feb; 38(2):414-6. PubMed ID: 17234987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A graphic reanalysis of the NINDS Trial.
    Hoffman JR; Schriger DL
    Ann Emerg Med; 2009 Sep; 54(3):329-36, 336.e1-35. PubMed ID: 19464756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
    Stroke; 2000 Dec; 31(12):2912-9. PubMed ID: 11108748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Added Benefit of Stent Retriever Technology for Acute Ischemic Stroke: A Pooled Analysis of the NINDS tPA, SWIFT, and STAR Trials.
    Saposnik G; Lebovic G; Demchuk A; Levy EI; Ovbiagele B; Goyal M; Johnston SC;
    Neurosurgery; 2015 Sep; 77(3):454-61. PubMed ID: 26280825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial body temperature in ischemic stroke: nonpotentiation of tissue-type plasminogen activator benefit and inverse association with severity.
    Kim SH; Saver JL
    Stroke; 2015 Jan; 46(1):132-6. PubMed ID: 25424482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
    Weintraub MI
    Stroke; 2006 Jul; 37(7):1917-22. PubMed ID: 16728683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators.
    Lyden P; Lu M; Jackson C; Marler J; Kothari R; Brott T; Zivin J
    Stroke; 1999 Nov; 30(11):2347-54. PubMed ID: 10548669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
    LaMonte MP; Bahouth MN; Magder LS; Alcorta RL; Bass RR; Browne BJ; Floccare DJ; Gaasch WR;
    Ann Emerg Med; 2009 Sep; 54(3):319-27. PubMed ID: 19101059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
    Chalela JA; Kasner SE; Jauch EC; Pancioli AM
    Stroke; 1999 Nov; 30(11):2366-8. PubMed ID: 10548672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.
    Broderick JP; Lu M; Kothari R; Levine SR; Lyden PD; Haley EC; Brott TG; Grotta J; Tilley BC; Marler JR; Frankel M
    Stroke; 2000 Oct; 31(10):2335-41. PubMed ID: 11022060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
    Soeteman DI; Menzies NA; Pandya A
    Value Health; 2017; 20(7):894-901. PubMed ID: 28712618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.